BRIEF-PainReform Announces Initial Topline Data For PRF-110 Phase 3 Clinical Trial

Reuters11-20 21:34

BRIEF-<a href="https://laohu8.com/S/PRFX">PainReform</a> Announces Initial Topline Data For PRF-110 Phase 3 Clinical Trial

Nov 20 (Reuters) - PainReform Ltd PRFX.O:

PAINREFORM ANNOUNCES INITIAL TOPLINE DATA FOR PRF-110 PHASE 3 CLINICAL TRIAL
PAINREFORM LTD - PRF-110 SHOWS STATISTICALLY SIGNIFICANT PAIN REDUCTION IN FIRST 48 HOURS
PAINREFORM LTD - DATA FOR SUBSEQUENT 24-HOUR PERIOD UNCLEAR DUE TO INCOHERENCE
PAINREFORM LTD - COLLABORATING WITH LOTUS TO RESOLVE DATA INCOHERENCE

Source text: ID:nGNX3BBYs

Further company coverage: PRFX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484162731?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484162731","market":"us","top_or_hot":-1,"title":"BRIEF-PainReform Announces Initial Topline Data For PRF-110 Phase 3 Clinical Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/PRFX\">PainReform</a> Announces Initial Topline Data For PRF-110 Phase 3 Clinical Trial</title></head><body><p><span>Nov 20 (Reuters)</span><span> - </span>PainReform Ltd <span>PRFX.O</span>:</p><ul><li><p>PAINREFORM ANNOUNCES INITIAL TOPLINE DATA FOR PRF-110 PHASE 3 CLINICAL TRIAL</p></li><li><p>PAINREFORM LTD - PRF-110 SHOWS STATISTICALLY SIGNIFICANT PAIN REDUCTION IN FIRST 48 HOURS</p></li><li><p>PAINREFORM LTD - DATA FOR SUBSEQUENT 24-HOUR PERIOD UNCLEAR DUE TO INCOHERENCE</p></li><li><p>PAINREFORM LTD - COLLABORATING WITH LOTUS TO RESOLVE DATA INCOHERENCE</p></li></ul><p>Source text: <span>ID:nGNX3BBYs</span></p><p>Further company coverage: <span>PRFX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-PainReform Announces Initial Topline Data For PRF-110 Phase 3 Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-PainReform Announces Initial Topline Data For PRF-110 Phase 3 Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 21:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUABJGPTD:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-PainReform Announces Initial Topline Data For PRF-110 Phase 3 Clinical TrialNov 20 (Reuters) - PainReform Ltd PRFX.O:PAINREFORM ANNOUNCES INITIAL TOPLINE DATA FOR PRF-110 PHASE 3 CLINICAL ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUABJGPTD:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRFX","symbol_name":"PainReform","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUABJGPTD:1","article_id":"2484162731","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484162731","pubTimestamp":1732109644,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-PainReform Announces Initial Topline Data For PRF-110 Phase 3 Clinical TrialNov 20 (Reuters) - PainReform Ltd PRFX.O:PAINREFORM ANNOUNCES INITIAL TOPLINE DATA FOR PRF-110 PHASE 3 CLINICAL TRIALP","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRFX":"PainReform","BK4007":"制药"},"translate_title":"BRIEF-PainReform公布PRF-110 3期临床试验的初始顶线数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRFX":0.9},"content_text":"BRIEF-PainReform Announces Initial Topline Data For PRF-110 Phase 3 Clinical TrialNov 20 (Reuters) - PainReform Ltd PRFX.O:PAINREFORM ANNOUNCES INITIAL TOPLINE DATA FOR PRF-110 PHASE 3 CLINICAL TRIALPAINREFORM LTD - PRF-110 SHOWS STATISTICALLY SIGNIFICANT PAIN REDUCTION IN FIRST 48 HOURSPAINREFORM LTD - DATA FOR SUBSEQUENT 24-HOUR PERIOD UNCLEAR DUE TO INCOHERENCEPAINREFORM LTD - COLLABORATING WITH LOTUS TO RESOLVE DATA INCOHERENCESource text: ID:nGNX3BBYsFurther company coverage: PRFX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484162731"}